| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3488 | 2010 |
| The pivotal role of hepatocytes in drug discovery MG Soars, DF McGinnity, K Grime, RJ Riley Chemico-biological interactions 168 (1), 2-15, 2007 | 201 | 2007 |
| Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo MG Soars, K Grime, JL Sproston, PJH Webborn, RJ Riley Drug metabolism and disposition 35 (6), 859-865, 2007 | 166 | 2007 |
| Time-dependent CYP inhibition RJ Riley, K Grime, R Weaver Expert opinion on drug metabolism & toxicology 3 (1), 51-66, 2007 | 160 | 2007 |
| The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions K Grime, RJ Riley Current drug metabolism 7 (3), 251-264, 2006 | 137 | 2006 |
| Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes DF McGinnity, AJ Berry, JR Kenny, K Grime, RJ Riley Drug metabolism and disposition 34 (8), 1291-1300, 2006 | 125 | 2006 |
| Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis A Atkinson, JR Kenny, K Grime Drug metabolism and disposition 33 (11), 1637-1647, 2005 | 116 | 2005 |
| Optimisation of DMPK by the inhaled route: challenges and approaches A E Cooper, D Ferguson, K Grime Current drug metabolism 13 (4), 457-473, 2012 | 107 | 2012 |
| Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods KH Grime, J Bird, D Ferguson, RJ Riley European Journal of Pharmaceutical Sciences 36 (2-3), 175-191, 2009 | 107 | 2009 |
| Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug MLT Vieira, B Kirby, I Ragueneau‐Majlessi, A Galetin, JYL Chien, ... Clinical Pharmacology & Therapeutics 95 (2), 189-198, 2014 | 90 | 2014 |
| The UK prospective diabetes study RC Turner, RR Holman Annals of medicine 28 (5), 439-444, 1996 | 85 | 1996 |
| Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics KH Grime, P Barton, DF McGinnity Molecular pharmaceutics 10 (4), 1191-1206, 2013 | 84 | 2013 |
| Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary … B Bonn, P Svanberg, A Janefeldt, I Hultman, K Grime Drug Metabolism and Disposition 44 (4), 527-533, 2016 | 82 | 2016 |
| Improving the accuracy of predicted human pharmacokinetics: lessons learned from the AstraZeneca drug pipeline over two decades M Davies, RDO Jones, K Grime, R Jansson-Löfmark, AJ Fretland, ... Trends in pharmacological sciences 41 (6), 390-408, 2020 | 77 | 2020 |
| Metabolic screening in vitro: metabolic stability, CYP inhibition and induction RJ Riley, K Grime Drug discovery today: Technologies 1 (4), 365-372, 2004 | 64 | 2004 |
| Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement K Grime, SW Paine Drug Metabolism and Disposition 41 (2), 372-378, 2013 | 59 | 2013 |
| HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes K Rubin, A Janefeldt, L Andersson, Z Berke, K Grime, TB Andersson Drug Metabolism and Disposition 43 (1), 119-125, 2015 | 57 | 2015 |
| Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5 MG Soars, K Grime, RJ Riley Xenobiotica 36 (4), 287-299, 2006 | 56 | 2006 |
| The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting CJ O'Donnell, K Grime, P Courtney, D Slee, RJ Riley Drug metabolism and disposition 35 (3), 381-385, 2007 | 45 | 2007 |
| Exploring concepts of in vitro time-dependent CYP inhibition assays DM Stresser, J Mao, JR Kenny, BC Jones, K Grime Expert opinion on drug metabolism & toxicology 10 (2), 157-174, 2014 | 41 | 2014 |
